Opinion & analysis

The Knowledge Within: An Interview With Merck KGaA’s R&D Chief

Merck KGaA’s head of global research and development, Luciano Rossetti, sat down with In Vivo to discuss the track the German company is taking toward becoming a major player in global immuno-oncology. Tap in to his insights and opinions in this essential interview.

Get a more in-depth analysis on Pharmaceutical market trends with our Opinion on Analysis reports.

The Knowledge Within: An Interview With Merck KGaA’s R&D Chief

Made In China Gene Therapy A Father’s Quest To Save Son With UltraRare Condition

New Year Present For Takeda As Shire Close Nears?

‘Something’s Going To Happen’: Former FDAer John Bailey On Cosmetics Reform Legislation

FDA’s Withdrawn Reg On Data Fraud Hangs Over Zolgensma Incident

Neuroscience Is The Next Oncology: Why Biogen Is Doubling Down

Drug/Device Combinations: Shock For Pharma As It Seeks Notified Body Resources Too

Bayer’s Consumer Chief Initiates Turnaround Plan In Bid To Return Troubled Business To Growth

Two First MDR Certificates Issued – Are Floodgates Open For Mass Certifications?

Standards, Not Predicates, Emphasized In Finalized Alternative 510(k) Pathway

Pharma Intelligence Report Store Article Collection Digital Policy & Regulation Report 1

Paying for Pharmaceutical Value: The Problem of a One-Size-Fits-All Definition

Going Generic: Big Brands Poised To Lose Marketing Exclusivity In The US In 2019

Reckitt Reaps ROI Reward In Geo-Targeted Symptoms App Promoting Mucinex, Delsym

GSK Woes Raise Big Pharma R&D Question

Investigator Horror Stories 3: Boozing On The Job? Yup, That Happened – As Have These Other Shocking Tales Of Irregular FDA Inspections

An FDA Age-Based Predicate Policy Would Be Arbitrary, Reg Experts Complain

Gene Therapy’s Next Big Challenge: Manufacturing

Lilly Prices Olumiant For JAK Battle, But Misses Approval For Higher Dose

Missed Opportunities: 10 Questions We Wish Senators Had Asked At The Drug Pricing Hearing

What Does 2019 Hold For Biopharma?

Cancer’s New Patient Demographic; Will Survivorship Change The Face Of Cancer Care?

Interventional Neurology: Cerebral Aneurysm and Arteriovenous Malformation Systems

Takeda To Press On With Core R&D Strategy Post-Shire

Moving Medical Affairs To The Pharma Forefront

Kratom Industry Offers Own Standards As Another Firm Warned About FDA Rules

Cancer Drug Combination Pricing: Genentech Offers Model For Tecentriq, Avastin

Father of Humira, Greg Winter, Wins 2018 Nobel Prize For Chemistry

In Vivo’s Quick Guide To Gene Therapy

Data, AI And Machine Learning Are Propelling Clinical Trials Data Analysis To New Heights

US FDA’s Temple on Real-world Evidence: “I Find the Whole Thing Very Frustrating”

‘Project Orbis’ Oncology Pilot Eventually Will Target ‘Major Impact’ Applications

Technology Gap Separates OTC Drug Firms From SelfCare Sales Growth

Abbott Launches New App To Keep Heart Failure Patients Out Of The Hospital

EU Beats Predicted Timelines And Appoints First UK Notified Body Against MDR

Unilever Seeks End To Litigation Over St. Ives Scrub, Plaintiffs’ ‘Fake Medical Condition’

Commission Would Back Limited Expansion Of Products Covered By MDR Grace Period

Focus More On Patients, Less On Hospitals, Experts Tell Device Companies

As Humira Biosimilars Arrive, Battle Lines Shift From Education To Sustainability

Roche: We’ve Abandoned Budgets And It’s Liberated Employees

Gottlieb’s Short Tenure Will Be Felt Long After He Leaves US FDA

Top 20 Pharma Ranks: As Some Move Up, Others Fall Down

Sanofi Releases Annual Drug Price Report Ahead Of Senate Hearing

From Device Centric To Disease Management: Ascensia Commits To Deeper Role In Diabetes

J&J CEO Sees Victory Ahead On Talc, Growth From Johnson’s Relaunch